Jaime E C Hallak
Overview
Explore the profile of Jaime E C Hallak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
141
Citations
3458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chaves C, Dos Santos R, Dursun S, Tusconi M, Carta M, Brietzke E, et al.
Front Psychiatry
. 2024 Nov;
15:1485337.
PMID: 39568756
No abstract available.
2.
da Costa Goncalves K, de Tavares V, de Morais Barros M, de Brito A, Cavalcanti-Ribeiro P, Palhano-Fontes F, et al.
Eur Arch Psychiatry Clin Neurosci
. 2024 Oct;
PMID: 39467856
This systematic review aims to elucidate the nexus between ketamine's psychoactive properties and its efficacy in treating a broad spectrum of psychiatric disorders. We searched three databases and used citation...
3.
Ferreira R, Martins R, Pires I, Marques B, Costa K, Lirio P, et al.
Brain Behav Immun Health
. 2024 Oct;
41:100855.
PMID: 39391797
Even though respiratory dysfunctions are the primary symptom associated with SARS-CoV-2 infection, cerebrovascular events, and neurological symptoms are described in many patients. However, the connection between the neuroimmune profile and...
4.
Genetic ablation of the isoform γ of PI3K decreases antidepressant efficacy of ketamine in male mice
Vaz G, Turcato F, Lima I, Scarante F, Araujo M, Brigante T, et al.
IBRO Neurosci Rep
. 2024 Jul;
17:87-95.
PMID: 39026898
About one-third of major depressive disorder (MDD) patients demonstrate unresponsiveness to classic antidepressants, and even the clinical efficacy of fast-acting drugs such as ketamine varies significantly among patients with treatment-resistant...
5.
Dos Santos R, da Silva Dias I, Zuardi A, Queiroz R, Guimaraes F, Hallak J, et al.
J Clin Psychopharmacol
. 2024 Jul;
44(5):472-480.
PMID: 39008875
Background: Agomelatine is an antidepressant drug that acts as an agonist of melatoninergic MT1/2 receptors and an antagonist of serotonergic 5-HT2C receptors. Studies suggest that agomelatine has anxiolytic properties in...
6.
Adelino M, Nunes M, Nunes M, Quarantini L, Hallak J, Lacerda A
Schizophr Res
. 2024 May;
269:114-115.
PMID: 38761435
No abstract available.
7.
Machado J, de Almeida V, Zuardi A, Hallak J, Crippa J, Vieira A
Acta Neuropsychiatr
. 2024 Mar;
36(5):330-336.
PMID: 38528655
Background: Cannabidiol (CBD) is one of the main cannabinoids present in female flowers. Previous investigation has already provided insights into the CBD molecular mechanism; however, there is no transcriptome data...
8.
Chaves C, Dursun S, Tusconi M, Hallak J
Front Psychiatry
. 2024 Feb;
15:1356975.
PMID: 38389990
No abstract available.
9.
Werle I, Nascimento L, Dos Santos A, Soares L, Dos Santos R, Hallak J, et al.
Br J Pharmacol
. 2024 Feb;
181(11):1671-1689.
PMID: 38320596
Background And Purpose: Ayahuasca (AYA) is a botanical psychedelic with promising results in observational and small clinical trials for depression, trauma and drug use disorders. Its psychoactive effects primarily stem...
10.
Pinto J, Crippa J, Cereser K, Vianna-Sulzbach M, Silveira Junior E, Santana da Rosa G, et al.
Can J Psychiatry
. 2023 Nov;
69(4):242-251.
PMID: 37920963
Objective: The treatment of bipolar depression remains challenging due to the limited effective and safe therapeutic options available; thus, developing newer treatments that are effective and well tolerable is an...